Deborah A. Zarin

Deborah A. Zarin

Auto-generated profile, based on publicly available information

Deborah A. Zarin

The MRCT Center of Brigham and Women’s Hospital and Harvard, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 1998 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
JWJ. C. West
J. C. West
DZD. A. Zarin
D. A. Zarin
BPB. D. Peterson
B. D. Peterson
HPH. A. Pincus
H. A. Pincus

20 August 2019 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
ATAthina Tatsioni
Athina Tatsioni
FKFotini B. Karassa
Fotini B. Karassa
SGSteven N. Goodman
Steven N. Goodman
DZDeborah A. Zarin
Deborah A. Zarin
DFDaniele Fanelli
Daniele Fanelli
JIJohn P.A. Ioannidis
John P.A. Ioannidis

1 May 2020 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
DZDeborah A. Zarin
Deborah A. Zarin
WCWilliam H. Crown
William H. Crown
BBBarbara E. Bierer
Barbara E. Bierer

15 December 2020 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
DZDeborah A Zarin
Deborah A Zarin
SRStephen Rosenfeld
Stephen Rosenfeld

25 May 2023 in Clinical Trials
Verified
Journal Article
Closed access
DDDavid L DeMets
David L DeMets
DZDeborah A Zarin
Deborah A Zarin
FRFrank Rockhold
Frank Rockhold
SESusan S Ellenberg
Susan S Ellenberg
TFThomas Fleming
Thomas Fleming
JWJanet Wittes
Janet Wittes
Clinical trials investigating novel or high risk interventions, or studying vulnerable participants, often use a data monitoring committee to oversee the progress of the trial. The data monitoring committee serves both an ethical and a scientific function, by protecting the interests of trial participants while ensuring the integrity of the trial results. A data monitoring committee charter, which typically describes the procedures by which data monitoring committees operate, contains details about the data monitoring committee’s organizational structure, membership, meeting frequency, sequential monitoring guidelines, and the overall contents of data monitoring committee reports for interim review. These charters, however, are generally not reviewed by outside entities and are rarely publicly available. The result is that a key component of trial oversight remains in the dark. We recommend that ClinicalTrials.gov modify its system to allow uploading of data monitoring committee charters, as is already possible for other important study documents and that clinical trialists take advantage of this opportunity to voluntarily upload the data monitoring committee charter for trials that have one. The resulting cache of publicly available data monitoring committee charters should provide important insights for those interested in a particular trial, as well as for meta-researchers who wish to understand and potentially improve how this important component of trial oversight is actually being applied.

1 February 2020 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
DZDeborah A. Zarin
Deborah A. Zarin
The ClinicalTrials.gov results database addresses problems with the published literature including publication bias, incomplete reporting of outcome measures an